一種新型心衰治療方法應(yīng)用一種類(lèi)似起搏器樣的設(shè)備來(lái)加強(qiáng)心臟泵功能。

這種新設(shè)備包括脈沖發(fā)生器叫做Optimizer系統(tǒng)，能夠?qū)㈦娦盘?hào)傳送至泵活動(dòng)中心區(qū)域的心肌中，“欺騙”其產(chǎn)生更多的細(xì)胞內(nèi)鈣離子，從而增加心臟泵功能和收縮的活力。入選一項(xiàng)臨床研究的患者正在接受這種設(shè)備的安全性和治療效能的研究。

Optimizer系統(tǒng)包括一種程序化的植入脈沖發(fā)生器、便攜式程序器、和兩個(gè)右心室導(dǎo)聯(lián)。起搏器側(cè)重于調(diào)節(jié)心臟節(jié)律，Optimizer系統(tǒng)則以一項(xiàng)叫做心臟收縮調(diào)制(CCM)的新技術(shù)為基礎(chǔ)。與起搏器信號(hào)不同，CCM信號(hào)是非刺激性的，意味著信號(hào)能夠在絕對(duì)不應(yīng)期傳送，而且不會(huì)啟動(dòng)新的收縮。根據(jù)研究人員的說(shuō)法，CCM信號(hào)觸發(fā)心臟細(xì)胞內(nèi)循環(huán)的鈣離子的反應(yīng)，能夠提高心肌收縮力量，而不會(huì)增加總體工作負(fù)荷。

Beth Israel 醫(yī)學(xué)中心(New York, NY, USA)心衰項(xiàng)目主任、在該醫(yī)院進(jìn)行的臨床試驗(yàn)的首席研究員Jill Kalman醫(yī)生說(shuō)：“在減少工作負(fù)荷的同時(shí)，增加心臟泵功能的潛能，能夠用于治療III級(jí)或者IV級(jí)心臟功能衰竭患者，”

Optimizer系統(tǒng)是由Impulse Dynamics(USA)集團(tuán)(Orangeburg, NY, USA)制造的， 這是Impulse Dynamics N.V. (Netherlands Antilles)公司的全資附屬公司。

Safer Blood-Gas Analysis System
 
An innovative new treatment for heart failure uses a pacemaker-like device to help strengthen the heart’s pumping power.

The new device involves a pulse generator called the Optimizer system that delivers electrical signals to the heart muscle in the midst of its pumping action, fooling it into producing more intracellular calcium and thereby increasing the heart’s ability to pump and contract. Patients are now being enrolled in a study to investigate the safety and efficacy of the device.

The Optimizer system consists of a programmable implantable pulse generator, a portable programmer, and two right-ventricle leads. While pacemakers focus on modulating the heart’s rhythm, the Optimizer system is based on new technology known as cardiac contractility modulation (CCM). Unlike pacemaker signals, CCM signals are non-excitatory, meaning they are delivered during the absolute refractory period and therefore cannot initiate a new contraction. According to the investigators, the result is that CCM signals trigger a response in the calcium that is cycling within the heart cells in a way that improves the strength of the heart muscle’s contraction, without adding to its overall workload.

“The potential to improve the heart’s pumping ability while decreasing its workload would present a significant development in treating patients with class III or class IV heart failure,” observed Jill Kalman, M.D., director of the heart failure program at Beth Israel Medical Center (New York, NY, USA) and lead investigator of the trial at the hospital.

The Optimizer system is manufactured by Impulse Dynamics (USA), Inc. (Orangeburg, NY, USA), a wholly owned subsidiary of Impulse Dynamics N.V. (Netherlands Antilles).